**Table 1.**

*Recent clinical studies of systemic treatment in malignant pleural mesothelioma.*

### *Recent Advances in Systemic Therapy for Malignant Pleural Mesothelioma… DOI: http://dx.doi.org/10.5772/intechopen.102511*

however, that regimen has not been approved in most countries. In recent years, ICIs have shown remarkable progress in treating MPM. Summaries of the major trials, with a focus on recent trials, are shown in **Table 1**. They include both salvage treatments and first-line treatments. Based on the CheckMate 743 trial results, the ICI-ICI combination of ipilimumab plus nivolumab could be considered a new standard front-line treatment.

Some unresolved problems should be investigated to make further improvements in the outcome of patients with MPM. One is the rapid drop-off in PFS observed among patients that receive ICIs. A recent study on patients with non-small cell lung cancer showed that ipilimumab plus nivolumab combined with 2 cycles of cytotoxic chemotherapy could reduce the rapid drop-offs in both PFS and OS [21]. Those results supported the notion that the ICI-chemotherapy combination should undergo further clinical development. Results are also anticipated from an ongoing trial that is testing a more aggressive strategy, with a combination of platinum, pemetrexed, atezolizumab, and bevacizumab (BEAT-meso, NCT03762018).
